Cardiff Oncology, Inc.
CRDF- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001213037
In the last 90 days, Cardiff Oncology, Inc. insiders filed 2 open-market purchases and 0 sales; 104 institutions reported holding it in 13F filings for Q2 2026, worth $24.2M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Cardiff Oncology, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 77 | 90 | +13 |
| Shares | 8.60M | 13.1M | +4.49M (+52.2%) |
| Value | $45.8M | $29.1M | −$16.8M (−36.6%) |
New holders (29)
Institutions that held Cardiff Oncology, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (16)
Institutions that held Cardiff Oncology, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Laurion Capital Management LP | 928,717 | $4.96M |
| EAM Investors, LLC | 161,903 | $864.6K |
| HRT Financial LP | 67,889 | $362.0K |
| Omers Administration Corp | 51,100 | $272.9K |
| Point72 Asia (Singapore) Pte. Ltd. | 49,892 | $266.4K |
| Brevan Howard Capital Management LP | 32,402 | $173.0K |
| Y-Intercept (Hong Kong) Ltd | 29,464 | $157.3K |
| Integrated Wealth Concepts LLC | 22,000 | $117.5K |
| Sherbrooke Park Advisers LLC | 16,148 | $86.2K |
| Atom Investors LP | 15,298 | $81.7K |
| LMR Partners LLP | 13,101 | $70.0K |
| CTC Alternative Strategies, Ltd. | 12,400 | $66.2K |
| Connor, Clark & Lunn Investment Management Ltd. | 10,105 | $54.0K |
| Bank of Montreal | 22,100 | $44.2K |
| Newbridge Financial Services Group, Inc. | 17 | $91 |
| Macquarie Group Ltd | 1,368 | $7 |